18 results about "Trabecular meshwork" patented technology

A system includes a light source configured to emit treatment light and an optical coherence tomography (OCT) device. The system further includes a surgical instrument including a distal portion configured to be inserted into an eye of a patient. An optical fiber is coupled to the light source and to the OCT device and (a) conducts the treatment light along the distal portion to be emitted from a tip of the distal portion and (b) conducts detection light from the OCT device along the distal portion to be emitted from the tip of the distal portion and conduct a reflected portion of the detection light to the OCT device. A controller obtains image data from the OCT device and operates the light source per the image data, e.g., selects a number of pulses for the treatment light based on a thickness of a trabecular meshwork apparent in the image data.

The present disclosure describes an optical probe for applying a laser light to at least the flat portion of the ciliary body and optionally other areas, such as the trabecular mesh, the ciliary crown and / or the ciliary sulcus of the eye, the present invention relates to methods, such as for treating glaucoma, reducing intraocular pressure (IOP), improving the outflow of aqueous humor from the eye, and / or reducing the accumulation of aqueous humor within the eye. The optical probe may be adapted for simultaneous treatment of a plurality of different regions, tissues, or eye bodies of the eye, or for sequential treatment of a plurality of different regions, tissues, or eye bodies of the eye.

Provided is an ophthalmic surgery instrument that allows an instrument suitable for excising a trabecular meshwork to be configured and allows a grip portion to be used for both first ophthalmic surgery such as trabeculectomy and second ophthalmic surgery. A first passage and a second passage for performing suction or supply of a perfusate are formed in a grip portion of an ophthalmic surgery instrument. An internal thread portion is formed at a tip end of the grip portion. A tip end member for first ophthalmic surgery has a single passage therein, and has a bent-shaped blade portion and an opening of the passage at a tip end thereof. The tip end member for first ophthalmic surgery and a tip end member for second ophthalmic surgery are selectively screwable to the internal thread portion.

This invention relates to a biopsy needle for trabecular meshwork tissue of the eye, belonging to the field of medical device technology. It solves the problem of large incisions caused by the large surgical incisions in traditional trabeculectomy procedures, where a scalpel is used to cut a block of ocular tissue containing the trabeculae and deep cornea and sclera. The invention includes a needle, a scraper unit, and a handle. The needle is connected to the handle, the scraper unit is disposed within the needle, and the handle is for the user to hold. The needle is inserted into the patient's eyeball, and the scraper unit is used to cut the trabecular meshwork and Schlemm's canal wall tissue. The scraper unit of this invention is a bendable scraper unit. The first, second, and third sections can form grooved hooks for hooking the trabecular meshwork and Schlemm's canal wall tissue. The grooved hooks of this invention are specifically designed to hook the trabecular meshwork and Schlemm's canal wall tissue, resulting in minimal trauma to the ocular incision.

The invention relates to application of a reagent for inhibiting STAT3 gene expression in treatment of oxidative damage of trabecular meshwork cells. According to the invention, a signal channel STAT3 to EIF4E to TGF-beta-SMAD < 2 / 3 > for regulating and controlling the oxidative damage of the trabecular meshwork cells is innovatively found, and the STAT3 activates the TGF-beta-SMAD < 2 / 3 > channel by combining with EIF4E3, so that the apoptosis, oxidative stress and fibrosis of the trabecular meshwork cells caused by the oxidative damage are promoted. After the expression of the STAT3 gene in trabecular meshwork cells is inhibited, the EIF4E3 level can be reduced, and the apoptosis, oxidative stress and fibrosis of the trabecular meshwork cells induced by EIF4E3 are improved. Therefore, a reagent for inhibiting STAT3 gene expression can be used for treating trabecular meshwork cell oxidative damage and eye diseases related to the trabecular meshwork cell oxidative damage, including glaucoma and the like.

An ab externo automated laser treatment system for treating an eye in a subject, includes a non-contact laser source configured to generate a laser beam having at least one wavelength to treat the eye by directing the laser beam from a location spaced from the eye, wherein the at least one wavelength is a near-infrared wavelength in the range of about 0.5-2.2 μm, a laser scanner optically coupled to the non-contact laser source to receive the laser beam from the non-contact laser source and to scan the laser beam relative to the eye, and a processor, and memory including stored computer-readable instructions that, responsive to execution by the processor, cause the laser treatment system to direct the laser beam to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser beam is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and / or ciliary body without photocoagulation of the tissue of the eye. Trans-pupillary systems, patient interfaces, and methods are also disclosed.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The invention discloses an application of 6-CEPN in preparation of a product for preventing and improving osteoporosis. According to the invention, ovariectomized mice are fed with two doses of 6-CEPN, which discovers that the 6-CEPN can obviously inhibit abnormal weight increase of the mice caused by estrogen decrease and can also improve bone microstructure of the ovariectomized mice; the bone trabecula network structure is adjusted by increasing the bone trabecula connection density, the bone trabecula number and the bone trabecula thickness and reducing the separation degree of the bone trabecula, meanwhile, 6-CEPN can further increase the bone density and the bone volume fraction of ovariectomized mice, increase the rigidity and deflection of bones and improve the bone strength, the effect of high-dose 6-CEPN is larger than that of low-dose 6-CEPN, and the effect of high-dose 6-CEPN is better than that of low-dose 6-CEPN. Therefore, the composition has a dose-dependent effect.

The application discloses a kind of drugs for treating glucocorticoid glaucoma.The application finds by experiment, Rho kinase inhibitor can inhibit RhoA-ROCK signal pathway, destroy glucocorticoid-induced cytoskeleton remodeling and reduce extracellular matrix deposition.At the same time, 10 μM or less concentration, no toxic side effects to cell growth, while significantly inhibiting RhoA-ROCK signal pathway.The experimental results suggest that RKI1447 can change the morphology of trabecular meshwork cells and inhibit cell migration, thereby regulating aqueous humor drainage, reducing intraocular pressure, and thereby treating glucocorticoid glaucoma.The application provides the application of Rho kinase inhibitor RKI1447 in the preparation of glucocorticoid glaucoma drugs.

The invention relates to the technical field of medicines, in particular to application of flos lonicerae and an extract thereof in preparation of a medicine for treating glaucoma. According to the application, the effects of the lonicera confusa extract and the active ingredients thereof on resisting trabecular meshwork cells and trabecular meshwork fibrosis are found, and the lonicera confusa extract and the active ingredients thereof can be applied to preparation of drugs for resisting trabecular meshwork fibrosis and preventing and treating trabecular meshwork fibrosis related diseases such as glaucoma. The invention relates to applications of lonicera confusa extract, chlorogenic acid, isochlorogenic acid A, dipsacus asper saponin B and macranthoidin B in preparation of drugs for resisting trabecular meshwork cell and animal fibrosis, and also can be used for preparing drugs for inhibiting up-regulation of FN, alpha-SMA and COL-1 protein levels and drugs for inhibiting up-regulation of transcription levels of FN1, ACTA2, COL1A1 and COL4A1, and particularly relates to applications of the lonicera confusa extract, chlorogenic acid, isochlorogenic acid A, dipsacus asper saponin B and macranthoidin B in preparation of drugs for resisting trabecular meshwork cell and animal fibrosis. Good patent medicine potential and wide development, transformation and clinical application values and prospects are realized.

The present application relates to the technical field of biological medicine, and in particular to a reagent for regulating an ALKBH5-ABCA1 axis and application of the reagent in preparation of a drug for treating glaucoma, wherein the reagent at least includes any one of a reagent for promoting expression of ALKBH5, a reagent for promoting expression of ABCA1, a reagent for inhibiting expression of METTL3, and a DNA methyltransferase inhibitor for a promoter region of ALKBH5 gene.The present application provides a reagent for targeting activation of ABCA1 or a reagent for specifically targeting delivery of ALKBH5 mRNA to a trabecular meshwork, and the reagents can effectively reverse lipid metabolism defects and significantly reduce intraocular pressure.The present application not only provides a novel treatment target based on epigenetics and metabolism for glaucoma, but also realizes a proof of concept of LNP-mRNA intraocular pressure reduction technology for the first time, and has a very high clinical conversion value.

The present application relates to the technical field of trabecular meshwork fenestration surgery, and discloses a method and device for predicting intraocular pressure parameters after trabecular meshwork fenestration surgery, which is based on a phase optical coherence imaging method to obtain the trabecular meshwork elasticity parameters of different sections in the patient's eye and the three-dimensional reconstructed intravenous image of the trabecular meshwork; the fluid collection tube features are extracted from the three-dimensional reconstructed intravenous image of the trabecular meshwork; the trabecular meshwork elasticity parameters and the fluid collection tube features are input into a trabecular meshwork tissue constitutive model to determine the target fenestration position of the trabecular meshwork, so as to simulate the trabecular meshwork fenestration surgery operation; based on the simulation result of the trabecular meshwork fenestration surgery operation, the intraocular pressure parameters after the trabecular meshwork fenestration surgery corresponding to the target fenestration position of the trabecular meshwork are predicted, and therefore, the success rate of the trabecular meshwork fenestration surgery can be finally improved.

The invention discloses an application of a proliferation-related 1-like 1 protein (SIPA1L1) as a drug target in preparation of a drug for preventing and / or treating glaucoma, and relates to the technical field of medical treatment. The present invention proposes that SIPA1L1 is elevated in human trabecular meshwork (TM) cells treated by aqueous humor and transforming growth factor-beta2 (TGF-beta2) in patients with primary open-angle glaucoma, which SIPA1L1 not only promotes the production of extracellular matrix (ECM) proteins in these cells, but also inhibits the degradation of ECM proteins by inhibiting phagocytosis. The SIPA1L1 disclosed by the invention is an important factor for regulating HTM cell biological functions, which has important significance on the pathogenesis of glaucoma and the treatment of glaucoma, in addition, the proliferation-related 1-like 1 protein (SIPA1L1) disclosed by the invention can be used as a drug target for preventing and / or treating other eye diseases. The method has a wide application prospect.

The utility model discloses a device capable of forming an opening in the trabecular meshwork of the eye, comprising a handle, a cutting element, a sheath tube and a pushing element, the cutting element comprises an elongated rod and two cutting blades, the tail of the elongated rod is fixedly connected with the head of the handle, and the head of the elongated rod is connected with the two cutting blades; the two cutting blades are symmetrically arranged with a predetermined opening, and the head of each cutting blade has a cutting part capable of penetrating into the trabecular meshwork and cutting the trabecular meshwork; the sheath tube is sleeved on the elongated rod and can slide along the elongated rod; the pushing element is connected with the handle and can drive the sheath tube to move towards the direction of the two cutting blades, so that the two cutting blades are closed to each other under the extrusion of the sheath tube to cut the trabecular meshwork, the cut tissue is easy to be peeled off from the trabecular meshwork, the cut part of the trabecular meshwork can form a trabecular meshwork opening, and the aqueous humor in the anterior chamber is promoted to flow out of the trabecular meshwork opening to reduce the intraocular pressure; and the size of the trabecular meshwork opening can be controlled during the cutting process.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

A system includes a light source configured to emit treatment light and an optical coherence tomography (OCT) device. The system further includes a surgical instrument including a distal portion configured to be inserted into an eye of a patient. An optical fiber is coupled to the light source and to the OCT device and (a) conducts the treatment light along the distal portion to be emitted from a tip of the distal portion and (b) conducts detection light from the OCT device along the distal portion to be emitted from the tip of the distal portion and conduct a reflected portion of the detection light to the OCT device. A controller obtains image data from the OCT device and operates the light source per the image data, e.g., selects a number of pulses for the treatment light based on a thickness of a trabecular meshwork apparent in the image data.

This invention discloses a pusher for adjusting and stabilizing the position of a titanium alloy stent during iStent inject W micro-scaffold implantation surgery, comprising: a handle with a push rod at one end; the push rod having one end connected to the handle and the other end equipped with a push ball; the push ball is a sphere with a diameter of 280-300 μm, and its surface has a frosted texture. This invention effectively fills the gap in the prior art for the lack of specialized instruments that can precisely adjust the position of micro-scaffolds, solves common problems such as loosening and positional displacement during micro-scaffold use, effectively enhances the stability and certainty of micro-scaffold implantation in trabecular mesh, avoids damage to surrounding tissues caused by blind pushing operations, ensures surgical efficacy, and improves surgical safety.

The present invention relates to a novel compound having a Rho kinase inhibitory ability, and a use thereof. The present invention has an excellent Rho kinase (ROCK) inhibitory ability and an excellent effect of inhibiting shrinkage of human trabecular meshwork (HTM) cells, and thus can be variously used as a pharmaceutical composition, a quasi-drug composition, a food composition and the like for preventing, alleviating, or treating glaucoma. In addition, the compound of the present invention is derived from a natural product, and has almost no side effects, and thus can be safely and continuously used.